Literature DB >> 24127682

Pattern recognition analysis for hepatotoxicity induced by acetaminophen using plasma and urinary 1H NMR-based metabolomics in humans.

Ji Won Kim1, Sung Ha Ryu, Siwon Kim, Hae Won Lee, Mi-sun Lim, Sook Jin Seong, Suhkmann Kim, Young-Ran Yoon, Kyu-Bong Kim.   

Abstract

Drug-induced liver injury (DILI) is currently an increasingly relevant health issue. However, available biomarkers do not reliably detect or quantify DILI risk. Therefore, the purpose of this study was to comparatively evaluate plasma and urinary biomarkers obtained from humans treated with acetaminophen (APAP) using a metabolomics approach and a proton nuclear magnetic resonance (NMR) platform. APAP (3 g/day, two 500 mg tablets every 8 h) was administered to 20 healthy Korean males (age, 20-29 years) for 7 days. Urine was collected daily before and during dosing and 6 days after the final dose. NMR spectra of these urine samples were analyzed using principal component analysis (PCA) and partial least-squares-discrimination analysis. Although the activities of aspartate aminotransferase and lactate dehydrogenase were significantly increased 7 days post-APAP treatment, serum biochemical parameters of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, γ-glutamyl transpeptidase, and lactate dehydrogenase were within normal range of hepatic function. However, urine and plasma (1)H NMR spectroscopy revealed different clustering between predosing and after APAP treatment for global metabolomic profiling through PCA. Urinary endogenous metabolites of trimethylamine-N-oxide, citrate, 3-chlorotyrosine, phenylalanine, glycine, hippurate, and glutarate as well as plasma endogenous metabolites such as lactate, glucose, 3-hydroxyisovalerate, isoleucine, acetylglycine, acetone, acetate, glutamine, ethanol, and isobutyrate responded significantly to APAP dosing in humans. Urinary and plasma endogenous metabolites were more sensitive than serum biochemical parameters. These results might be applied to predict or screen potential hepatotoxicity caused by other drugs using urinary and plasma (1)H NMR analyses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24127682     DOI: 10.1021/ac402390q

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  22 in total

1.  Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen.

Authors:  R D Fannin; K Gerrish; S O Sieber; P R Bushel; P B Watkins; R S Paules
Journal:  Clin Pharmacol Ther       Date:  2016-02-22       Impact factor: 6.875

Review 2.  An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.

Authors:  Javier De Las Heras; Luis Aldámiz-Echevarría; María-Luz Martínez-Chantar; Teresa C Delgado
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-11-28       Impact factor: 4.481

Review 3.  The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.

Authors:  Marta Moreno-Torres; Guillermo Quintás; José V Castell
Journal:  Metabolites       Date:  2022-06-19

Review 4.  Medicinal Thiols: Current Status and New Perspectives.

Authors:  Annalise R Pfaff; Justin Beltz; Emily King; Nuran Ercal
Journal:  Mini Rev Med Chem       Date:  2020       Impact factor: 3.862

Review 5.  Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review.

Authors:  Abdul-Hamid Emwas; Claudio Luchinat; Paola Turano; Leonardo Tenori; Raja Roy; Reza M Salek; Danielle Ryan; Jasmeen S Merzaban; Rima Kaddurah-Daouk; Ana Carolina Zeri; G A Nagana Gowda; Daniel Raftery; Yulan Wang; Lorraine Brennan; David S Wishart
Journal:  Metabolomics       Date:  2014-11-21       Impact factor: 4.290

Review 6.  Biomarkers in DILI: One More Step Forward.

Authors:  Mercedes Robles-Díaz; Inmaculada Medina-Caliz; Camilla Stephens; Raúl J Andrade; M Isabel Lucena
Journal:  Front Pharmacol       Date:  2016-08-22       Impact factor: 5.810

Review 7.  Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.

Authors:  Naomi J Rankin; David Preiss; Paul Welsh; Naveed Sattar
Journal:  Int J Epidemiol       Date:  2016-10-27       Impact factor: 7.196

8.  Toxic Markers of Matrine Determined Using (1) H-NMR-Based Metabolomics in Cultured Cells In Vitro and Rats In Vivo.

Authors:  Zhonghuang Li; Liang Zheng; Jian Shi; Guiyu Zhang; Linlin Lu; Lijun Zhu; Jiajie Zhang; Zhongqiu Liu
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-30       Impact factor: 2.629

Review 9.  Recommendations and Standardization of Biomarker Quantification Using NMR-Based Metabolomics with Particular Focus on Urinary Analysis.

Authors:  Abdul-Hamid Emwas; Raja Roy; Ryan T McKay; Danielle Ryan; Lorraine Brennan; Leonardo Tenori; Claudio Luchinat; Xin Gao; Ana Carolina Zeri; G A Nagana Gowda; Daniel Raftery; Christoph Steinbeck; Reza M Salek; David S Wishart
Journal:  J Proteome Res       Date:  2016-01-20       Impact factor: 4.466

Review 10.  The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?

Authors:  Paula Iruzubieta; Maria Teresa Arias-Loste; Lucía Barbier-Torres; Maria Luz Martinez-Chantar; Javier Crespo
Journal:  Biomed Res Int       Date:  2015-12-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.